EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment

Jacob Levi iD, Junzheng Wang iD, Francois Venter iD, Andrew Hill iD

Obesity · 2023-05 · 31 (5) · 1270-1279

DOI: 10.1002/oby.23725 ↗

At a glance

Journal article in Obesity, published online on 2023-02-23. Written by Jacob Levi and 3 co-authors. Institution: Intensive Care Medicine, Royal Free Hospital NHS Trust, London, UK. Major MEDLINE topics: Liraglutide, Anti-Obesity Agents. Cited 71 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NHLBI NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

Novel antiobesity treatments are highly effective in recent clinical trials. Access to these medications is needed to supplement lifestyle and surgical interventions for millions living with obesity worldwide, but high prices are limiting. This study aimed to review current treatment costs and calculate potential estimated minimum prices (EMPs).

Methods

The authors searched national drug price databases across various countries for orlistat, naltrexone‐bupropion, topiramate‐phentermine, liraglutide, semaglutide, and tirzepatide. EMPs for antiobesity medications were calculated using established methodology, using active pharmaceutical ingredients (API) from the Panjiva database. EMPs were calculated per 30‐day course and include costs of active pharmaceutical ingredients, excipients, formulation, taxation, and 10% profit margin.

Results

National prices of antiobesity medications were significantly higher than calculated EMPs. Semaglutide 30‐day course prices ranged from $804 (United States) to $95 (Turkey) while the EMP was $40. Liraglutide prices ranged from $1418 (United States) to $252 (Norway) while the EMP was $50. Some oral treatments could be generically manufactured at very low costs per course ($7 for orlistat; $5 for phentermine/topiramate combination tablets), while naltrexone/bupropion was more expensive ($54).

Conclusions

This study shows that certain weight loss treatments can be manufactured and sold profitably at low costs, but prices currently range widely between countries, limiting access for those in need.

Subjects

MeSH terms (MEDLINE)

LiraglutideAnti-Obesity AgentsOrlistatTopiramateNaltrexoneBupropionDrug CombinationsPhentermineHealth Care CostsHealth Services Accessibility

Substances

OrlistatTopiramateLiraglutideNaltrexoneBupropionDrug CombinationsAnti-Obesity AgentsPhentermine

Authors and institutions

  • Intensive Care Medicine, Royal Free Hospital NHS Trust, London, UK.
  • Medical Sciences Office, Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.
  • Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK.

ORCID profiles: Jacob Levi, Junzheng Wang, Francois Venter, Andrew Hill

Funding

  • NHLBI NIH HHS

Cite

APA

Levi, J., Wang, J., Venter, F., & Hill, A. (2023). Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity, 31(5), 1270-1279. https://doi.org/10.1002/oby.23725

Vancouver

Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity. 2023;31(5):1270-1279. doi:10.1002/oby.23725

BibTeX
@article{Levi2023,
  author = {Levi, Jacob and Wang, Junzheng and Venter, Francois and Hill, Andrew},
  title = {Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment},
  journal = {Obesity},
  year = {2023},
  volume = {31},
  number = {5},
  pages = {1270--1279},
  doi = {10.1002/oby.23725}
}
Start for free →